The mTOR pathway in hepatic malignancies

Mamatha Bhat, Nahum Sonenberg, Gregory J. Gores

Research output: Contribution to journalReview article

61 Scopus citations

Abstract

The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor-initiating pathway in hepatocellular carcinoma, with up-regulation seen in up to 50% of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate-activated protein kinase, has been shown to decrease liver carcinogenesis in population studies. mTOR inhibitors such as everolimus have been evaluated as adjunctive chemotherapy with some success, although efficacy has been limited by the lack of complete mTOR pathway inhibition. The active site mTOR inhibitors hold greater promise, given that they offer complete mTOR suppression. There is also evidence of mTOR pathway activation in cholangiocarcinoma, although its biological significance in initiating and promoting tumor progression remains ambiguous. This review provides an overview of the complex biochemistry behind the mTOR pathway and its role in carcinogenesis, especially as it pertains to hepatic malignancies.

Original languageEnglish (US)
Pages (from-to)810-818
Number of pages9
JournalHepatology
Volume58
Issue number2
DOIs
StatePublished - Aug 1 2013

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'The mTOR pathway in hepatic malignancies'. Together they form a unique fingerprint.

  • Cite this